No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients

Ajay J. Iyengar, David S.Winlaw, John C. Galati, Gavin R. Wheaton, Thomas L. Gentles, Leeanne E. Grigg, Robert N. Justo, Dorothy J. Radford, Chantal Attard, Robert G.Weintraub, Andrew Bullock, Gary S. Sholler, David S. Celermajer, Yves d'Udekem, Australia and New Zealand Fontan Registry

Research output: Contribution to journalArticle

Abstract

Objectives: The most effective method of long-term thromboprophylaxis after the Fontan procedure is not clear. We compared the rates of thromboembolic events between patients receiving aspirin and warfarin after an extracardiac conduit Fontan procedure in a bi-national registry. 

Methods: All patients who underwent an extracardiac conduit Fontan procedure from 1997 to 2010 in Australia and New Zealand were identified. Medication status and routine follow-up and echocardiographic data were obtained from all patients. Survival analysis with propensity score matching and adjustment was performed to determine the treatment effect of warfarin compared with that of aspirin beyond the first year of follow-up, after which time patients had settled on their long-term thromboprophylaxis strategy. 

Results: Of 570 eligible patients, the data of 475 patients who were regularly followed up without mechanical valve replacement were available for analysis. Long-term thromboprophylaxis consisted of warfarin in 301 patients (63%), aspirin in 157 (33%) and none in 17 (4%). The 10-year rate of freedom from all thromboembolic events was 91% [95% confidence interval (CI) 88-94%]. Thromboembolic events beyond the first year of follow-up occurred in 18 patients (6 on aspirin and 12 on warfarin). After (i) propensity score adjustment and (ii) matching yielding 164 pairs, the hazard rates of thromboembolic events beyond the first year were not statistically different between the warfarin and aspirin groups [(i) hazard ratio (HR) 2.3, 95% CI 0.7-7.4, P = 0.2 and (ii) HR 1.5, 95% CI 0.5-4.7, P = 0.5, respectively]. 

Conclusions: No difference in the hazard rates of late thromboembolic events was observed between aspirin and warfarin beyond the first year after the extracardiac conduit Fontan procedure.

Original languageEnglish
Pages (from-to)980-987
Number of pages8
JournalEuropean Journal of Cardio-Thoracic Surgery
Volume50
Issue number5
DOIs
Publication statusPublished - Nov 2016
Externally publishedYes

Fingerprint Dive into the research topics of 'No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients'. Together they form a unique fingerprint.

  • Cite this

    Iyengar, A. J., S.Winlaw, D., Galati, J. C., Wheaton, G. R., Gentles, T. L., Grigg, L. E., Justo, R. N., Radford, D. J., Attard, C., G.Weintraub, R., Bullock, A., Sholler, G. S., Celermajer, D. S., d'Udekem, Y., & Australia and New Zealand Fontan Registry (2016). No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients. European Journal of Cardio-Thoracic Surgery, 50(5), 980-987. https://doi.org/10.1093/ejcts/ezw159